Skip to main content

Table 2 Mean percent blood glucose reduction in diabetic rats (N = 6)

From: Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models

Time

(h)

Gliclazide

Efavirenz

Efavirenz + Gliclazide (Single dose treatment)

Efavirenz + Gliclazide (Multiple dose treatment)

1

32.92 ± 1.95

-04.55 ± 2.55

24.83 ± 1.98**

28.26 ± 1.62

2

42.05 ± 1.73

-05.08 ± 2.46

30.02 ± 1.59***

36.39 ± 1.89*

3

31.21 ± 1.74

-03.21 ± 2.41

20.70 ± 1.31***

25.45 ± 1.93*

4

25.13 ± 1.77

-02.40 ± 2.24

16.78 ± 2.21***

20.78 ± 1.36*

6

36.14 ± 1.56

03.99 ± 1.97

22.15 ± 1.34***

30.12 ± 1.47*

8

44.05 ± 1.55

04.45 ± 2.26

32.01 ± 1.39***

38.27 ± 1.42*

10

28.56 ± 1.87

05.39 ± 1.72

16.25 ± 2.25***

20.89 ± 1.49**

12

24.66 ± 2.32

04.28 ± 1.53

08.49 ± 2.32***

11.31 ± 2.17***

  1. ***Significant at P < 0.001 compared to gliclazide control
  2. **Significant at P < 0.01 compared to gliclazide control
  3. *Significant at P < 0.05 compared to gliclazide control